ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
The Relationship Between Visceral Fat Obesity and the Atherogenic Combined Index in Patients with Type 2 Diabetes Mellitus.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The presence of abdominal obesity, characterized by an accumulation of visceral fat area (VFA), has been identified as a significant risk factor for the development of type 2 diabetes mellitus (T2DM) and its associated complications. Substantial evidence has proven that it's strongly associated with lipid metabolism. The atherogenic combined index (ACI) is a novel non-traditional lipid index, but there is no clear evidence to explore the relationship with visceral fat obesity (VFO). Our study aimed to interpret this relationship in T2DM. Methods: In accordance with the research objective, this cross-sectional study retrospectively included 2,323 patients with T2DM from February 2020 to March 2023. The clinical and biochemical data were measured. VFA measurement was conducted at the umbilicus level using a dual bioelectrical impedance analysis. VFO was redefined as VFA ≥ 100 cm Results: The incidence of VFO was found to be higher among males than females. Among participants of both genders, the level of ACI was found to be significantly increased in the VFO group compared with the non-VFO group (both p < 0.001). As the ACI increased, the incidence of VFO increased concomitantly. Univariate correlation analysis revealed a positive correlation between ACI and VFO (correlation coefficient: 0.223, p < 0.001 in females; correlation coefficient: 0.302, p < 0.001 in males). Logistic regression analysis indicated that ACI was associated with VFO independently (OR: 1.797, p = 0.029 in females; OR: 2.501, p < 0.001 in males). Conclusion: The ACI had been found to be independently correlated with VFO in patients with T2DM in both genders. This finding had the potential to facilitate the monitoring and management of VFO in T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.